Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, with few effective therapeutic options for advanced disease. At least 40% of HCCs are clonal, potentially arising from STAT3 þ , NANOG þ and OCT3/4 þ liver progenitor/stem cell transformation, along with inactivation of transforming growth factor-beta (TGF-b) signaling. Here we report significantly greater signal transducer and activator of transcription 3 (STAT3) and tyrosine phosphorylated STAT3 in human HCC tissues (Po0.0030 and Po0.0455, respectively) than in human normal liver. Further, in HCC cells with loss of response to TGF-b, NSC 74859, a STAT3-specific inhibitor, markedly suppresses growth. In contrast, CD133 þ status did not affect the response to STAT3 inhibition: both CD133 þ Huh-7 cells and CD133 -Huh-7 cells are equally sensitive to NSC 74859 treatment and STAT3 inhibition, with an IC 50 of 100 lM. Thus, the TGF-b/beta2 spectrin (b2SP) pathway may reflect a more functional 'stem/progenitor' state than CD133. Furthermore, NSC 74859 treatment of Huh-7 xenografts in nude mice significantly retarded tumor growth, with an effective dose of only 5 mg/kg. Moreover, NSC 74859 inhibited tyrosine phosphorylation of STAT3 in HCC cells in vivo. We conclude that inhibiting interleukin 6 (IL6)/STAT3 in HCCs with inactivation of the TGF-b/b2SP pathway is an effective approach in management of HCCs. Thus, IL6/STAT3, Introduction Hepatocellular carcinoma (HCC) is the fifth most common cancer and third most frequent cause of cancer deaths worldwide, with 600 000 new cases diagnosed every year. Seventy per cent of HCC cases are found to be ineligible for potentially curative surgical therapy because of the disease reaching an advanced stage at the time of diagnosis. At present chemotherapy is for the most part ineffective and patients often have significant liver dysfunction; the median survival is from 6 to 16 months (Kew et al., 1971; Investigators TCotLIPC, 1998) . One potential mechanism of HCC resistance to chemotherapy may lie in the plasticity of the cell of origin, which is often a dysfunctional progenitor or stem cell. Up to 40% of HCCs are clonal and thus are considered to originate from progenitor/stem cells (Alison, 2005; Roskams, 2006; Zender et al., 2006; Tang et al., 2008) . In addition, several signaling pathways, such as signal transducer and activator of transcription 3 (STAT3), NOTCH, hedgehog and transforming growth factor-beta (TGF-b), which are involved in stem cell renewal, differentiation and survival, are commonly deregulated in HCC (Dando et al., 2005; Sicklick et al., 2006a, b; Kitisin et al., 2007; Nguyen et al., 2007; Wurmbach et al., 2007; Yeoh et al., 2007) . We and others have identified TGF-b pathway inactivation in HCCs that have a stem cell phenotype (Tang et al., 1998; Im et al., 2001; Kanzler et al., 2001; Kitisin et al., 2007) .
Transforming growth factor-beta pathway proteins are critical regulators of neuronal, hematopoietic, mesenchymal and epithelial cell lineages, as well as suppressors of carcinogenesis (Massague et al., 2000) . The TGF-b signaling pathway is activated upon ligand binding to the type I and II transmembrane receptor serine-threonine kinases; TGF-b receptor I (TGFBR1) and TGF-b receptor II (TGFBR2), respectively. Activated TGFBR1 subsequently phosphorylates SMAD transcription factors, such as receptor-regulated SMAD3, resulting in heterodimerization with the common mediator SMAD4, SMAD3/SMAD4 nuclear translocation and activation (or repression) of TGF-b target genes. The non-pleckstrin homology (PH) domain b-general-spectrin, b2SP (also known as Embryonic Liver Fodrin isoform, ELF or Spectrin b, non-erythrocytic 1 isoform 2), is crucial for SMAD regulation and cell specificity. b2SP (Embryonic liver fodrin) associates with SMAD3, presenting it to the cytoplasmic domain of the TGF-b receptor complex. Further, b2SP facilitates nuclear translocation and target gene activation by SMAD3 (Tang et al., 2003) . Dysfunction of TGF-b pathway members, such as TGFBR2, SMAD3, SMAD4 and b2SP, may lead to progenitor/stem cell deregulation, and cancer could ensue.
Recently, we identified putative liver progenitor or stem cells from human living-donor liver transplant specimens. These normal human progenitor/stem cells expressed the stem cell markers STAT3, OCT4 (POU5F1) and NANOG, as well as the TGF-b signaling proteins TGFBR2 and b2SP (Kitisin et al., 2007) . In contrast, we also showed that, in human HCC tissues, STAT3/OCT4-positive cells are strikingly negative for TGFBR2 and b2SP. Therefore, STAT3/OCT4-positive HCC cells, which have dysfunctional TGF-b signaling, are likely cancer progenitor cells that have the potential to give rise to HCCs, similar to the HCCs that develop in the Elf mutant mice with loss of response to TGF-b (Kitisin et al., 2007) . Using mouse genetics, we were able to modify STAT3 signaling in the b2SP (Elf) mutant mice and markedly reduce HCC formation.
The STAT3 inhibitor, NSC 74859 (also known as S3I-201), was discovered through virtual screening as an inhibitor of the Src homology 2 (SH2) dimerization domain of STAT3. When NSC74859 inhibits STAT3 dimerization, it inhibits target gene activation (Siddiquee et al., 2007) . In this study, we show that NSC 74859 suppresses growth of HCC cells in culture and in xenograft assays. Seven HCC cell lines were used in these studies. HepG2 cells were used as controls as TGF-b signaling is intact in this cell line (Cabibbo et al., 1998) . We show that two cell lines in addition to HepG2 cells, PLC/PRF/5 and SUN-449, have intact TGF-b signaling and that four cell lines, Huh-7, SNU-398, SNU-475 and SNU-182, have defective TGF-b signaling. Although the levels of STAT3 and p Y705 STAT3 are similar among the seven cell lines, the levels of p S727 STAT3 are lowered by a factor of two and four, respectively, in cells with impaired TGF-b signaling compared with the cell lines with intact TGF-b signaling. In addition, the cells with impaired TGF-b signaling are four times as sensitive to the STAT3 inhibitor NSC 74859. Our data suggest that TGF-b signals influence serine phosphorylation of STAT3. Thus, HCC cells with dysfunctional TGF-b signaling may be particularly sensitive to STAT3 inhibition.
To determine whether CD133 represented a further functional marker for HCC 'cancer stem cells (CSCs)', we assessed the response of HCC cells to STAT3 inhibition using antibodies to the stem cell surface marker CD133. CD133 is highly upregulated during early and post liver regeneration (Suetsugu et al., 2006; Ma et al., 2007; Yin et al., 2007) . CD133
þ Huh-7 cells are also twice as resistant to doxorubicin compared with CD133 À cells . STAT3 levels by western blot was precluded by the expression of these proteins in neutrophil and microphage, which invariably contaminates these samples. Therefore, semiquantitative analyses of the immunohistochemically stained samples were used to determine whether STAT3 and p Y705 STAT3 expression is significantly correlated with HCC. Intense ( þ þ þ ) and moderate ( þ þ ) STAT3 immunostaining was observed in eight of nine HCC samples, whereas none of the five normal liver samples were more than weakly stained (Figures 1a-d 
Isolation and inhibition of liver cancer stem cells
A progenitor/stem cell side population was isolated from the Huh-7 cell line by CD133 selection using MACS MicroBeads Cell Separation Technology . As few as five of these CD133 þ cells could form a colony on soft agar, whereas at least 100 unsorted Huh-7 cells were required to form one colony. Therefore, CD133
þ cells are enriched in progenitor/ stem cells (Figure 4d ). In addition, CD133
þ Huh-7 cells expressed a level of the stem cell marker CD44 that was four times those of CD133 À cells, and diminished levels of TGFBR2 (Figure 4b) .
We determined the sensitivity of CD133 þ and CD133 -cell populations to growth inhibition by NSC 74859 using the MTT cell proliferation assay. CD133 þ cells were as sensitive as CD133 -cells to STAT3 inhibition by NSC 74859. Both CD133 þ and CD133 -Huh-7 cells were inhibited by NSC 74859, and with comparable IC 50 concentrations of 100 mM (Figure 4a ). These results are significant as cancer progenitor/stem cells are thought to be more resistant to chemotherapy in general, and yet a hitherto well-described CSC marker, CD133 þ , did not reflect or predict the response of these HCC cells to treatment, whereas the TGF-b pathway inactivation was a positive predictive marker. Potentially, loss of the tumor suppressor TGF-b pathway indicates a key functional aspect of such CSCs and their response to therapeutics that target stem cells such as STAT3 inhibitors.
Inhibition of signal transducer and activator of transcription 3 with NSC 74859 results in HCC tumor regression As an in vivo test of the STAT3 inhibitor, NSC 74859, on late-stage tumors, we generated HCC tumor xenografts by injecting Huh-7 cells into the rear hindquarters of nude mice. Once the tumor size reached 0.176 ± 0.076 cm 3 for the control group and 0.164 ± 0.065 cm 3 for the treatment group (no significant size difference between tumors at day zero), NSC 74859 or vehicle alone was injected intraperitoneally at 5 mg/kg, and tumor measurements were taken every 2-3 days after drug injection. As early as 6 days after injection, tumors from treated mice were significantly smaller (Po0.01) than tumors from untreated mice (0.171 ± 0.038 and 0.43 ± 0.199 cm 3 , respectively; Figure 5 ). At 21 days after the start of NSC 74859 treatments, tumors from the treated mice were significantly smaller Figure 5a ). In fact, tumor growth was significantly retarded for the duration of the experiment (Figure 5a ). Importantly, all treated mice tolerated NSC 74859 well, showing no apparent signs of ill health. There is no difference in Owing to their low abundance (1 in 40-100 000), normal (non-embryonic) stem cells are difficult to isolate. Although the mechanism of CSC development remains in question, cells that have an increased ability to initiate tumors and to express stem cell markers have been isolated. Side-population analysis and cell sorting with stem cell surface markers CD133, CD44 and CD24 have been used for enriching CSC populations, which allowed phenotypic studies of these progenitor/stem-like cells. CD133 þ cells in glioblastoma have been found to be resistant to etoposide, paclitaxel, temozolomide and carboplatin (Liu et al., 2006) , and they express high levels of markers of neural precursors CD90, CD44, CXCR4, NESTIN, MSII and MELK compared with their CD133 counterparts. We find that HCC cells independent of CD133 þ status, but with loss of b2SP, are sensitive to NSC 74859, reflecting that b2SP status may reflect a more functional CSC phenotype than CD133 in HCC. Therefore, STAT3 may be an effective target for disrupting HCC progenitor/stem cells with inactivation of the TGF-b/b2SP pathway irrespective of CD133. Genetic knock-in models show that CD133 is in fact expressed on a multitude of differentiated epithelial cells in adult mouse tissues and on spontaneous primary colon tumors in mice. In primary human colon tumors, all of the epithelial cells also expressed CD133, and, surprisingly, CD133 þ and CD133 À populations were equally capable of tumor initiation in xenografts. In light of our findings that are supported by others, the role of CD133 as a marker of liver and gastrointestinal 'cancer stem cells' may need to be revised (LaBarge and Bissell, 2008; Shmelkov et al., 2008) .
Microarray and proteomic analyses of human and mouse HCC tissues with aberrant TGF-b signaling showed increased expression of the IL6/STAT3, wingless-type MMTV intergration site family (WNT) and cyclin-dependent kinase 4 signaling pathways (Kitisin et al., 2007) . Here, we focus on the potential role of activated STAT3 in HCC. Signal transducer and activator of transcription 3 is activated by tyrosine phosphorylation at Tyr 705 (p Y705 STAT3) in response to cytokines and growth factors (Aaronson and Horvath, 2002) . Phosphorylation of Tyr 705 is required for STAT3 activity, whereas Ser 727 phosphorylation (p S727 STAT3) positively regulates transcriptional activity but negatively affects its DNA-binding activity (Wen et al., 1995; Chung et al., 1997; Cao, 1999, 2001) . Importantly, STAT3 is a stem cell renewal factor, and hyperactive STAT3 signaling results in enhanced liver progenitor cell proliferation (Yeoh et al., 2007) . In addition, overexpression of a constitutively active form of STAT3 in immortalized rat or mouse fibroblasts induced tumors in nude mice (Bromberg et al., 1999) . Owing to its role in modulating stem cell survival, proliferation and transformation, STAT3 is thought to be critical for CSC survival in some tissues (Zhou et al., 2007) . In this study, we found elevated STAT3 and p Y705 STAT3 expression in HCC tissue, which is consistent with recent data showing an association of pSTAT3 with the histological grade of HCC tissue from 67 patients . Hence, disruption of TGF-b signaling and activation of STAT3 are important molecular events in the transformation of normal liver stem cells to cancer progenitor/stem cells. We thus propose STAT3 as a promising therapeutic target for HCC.
In this study, we show upregulation of STAT3 and p Y705 STAT3 levels in HCC. In HCC cell lines, we show equal amounts of STAT3 and p Y705 STAT3. However, there is less p S727 STAT3 in cells with lower levels of the TGF-b pathway proteins TGFBR2 and/or b2SP. These data suggest a reciprocal relation between IL6/STAT3 and TGF-b signaling in tumorigenic transformation, although a direct interaction between these two pathways is yet to be defined. Signal transducer and activator of transcription 3 inhibition suppresses the proliferation of HCC cells, with the most potent effect observed in cells with a dysfunctional TGF-b pathway, which also correlates with decreased p S727 STAT3 levels in these cells. Regulation of STAT3 serine phosphorylation by TGF-b throughthe TGF-b-activated kinase 1-Nemolike kinase (TAK1-NLK) cascade has been shown in Xenopus mesoderm induction (Ohkawara et al., 2004) . In addition, STAT3 interacts with TAK1 and Nemolike kinase as a scaffold, and this interaction leads to STAT3 phosphorylation at serine 727 and activation of Nemolike kinase (Kojima et al., 2005) . These studies suggest a mechanism by which TGF-b regulates serine phosphorylation of STAT3 and provide some thoughts for the sensitivity of HCC progenitor/stem cells with dysfunctional TGF-b signaling to the STAT3 inhibitor NSC 74859.
It is interesting to note that NSC 74859 is far more potent in vivo than in vitro, with an IC 50 of 100 mM in vitro, but an effective dosage of only 5 mg/kg in vivo. The same differences between in vivo and in vitro effective doses were observed when NSC 74859 was used to treat breast cancer (Siddiquee et al., 2007) . NSC 74859 inhibits breast carcinoma MDA-MB-435, MDA-MB-453 and MDA-MB-231 cell lines with an IC 50 close to 100 mM in vitro, but in vivo it effectively retards the growth of MDA-MB-231 cells at 5 mg/kg. One potential reason could be that NSC 74859 inhibits stroma and endothelial compartments in addition to the tumor cells, giving stronger in vivo and thus potentially realistic inhibition.
Recently, the US Food and Drug Administration approved sorafenib for the treatment of advanced HCC; it improves median overall survival by 3 months compared with placebo. As the first systemic agent to show survival benefits in patients with HCC, the clinical benefits remain modest. There is still an urgent need for therapies for this highly lethal disease. Modulation of STAT3 signaling in cancer progenitor cells may provide an important approach for new therapeutics in cancers with a poor prognosis such as HCC. Another feature offered by STAT3 inhibition for cancer therapy is its specificity-that it is only one of two possible molecular TGF-b/IL6 signals in human hepatocellular carcinoma L Lin et al targets (STAT3 and STAT5) as opposed to a multitude of tyrosine kinases that could potentially serve a similar function, thus reducing toxicities. Indeed, b2SP expression may represent a good predictive marker for response of HCC to new therapeutics targeting CSCs such as STAT3 inhibitors. Activities against tumor vasculature and good tolerability in animals serve as additional advantages of the STAT3 inhibitor. Indeed, our tests using the STAT3-specific drug NSC 74859 might be the type of approach needed for improving advanced HCC outcome, particularly in hepatocellular carcinomas with loss of TGF-b signaling.
Materials and methods

Cancer specimens
Formalin-fixed and paraffin-embedded HCC and normal liver specimens were obtained from the Georgetown University Division of Transplant Surgery, Washington, DC, USA. In all, nine HCC samples were collected from patients with varying grades and stages of cancer. Two independent blinded pathologists evaluated the tumors used in this study. The control samples of normal liver tissue used in the present investigation were taken from the borders of the surgical specimens. All specimens were collected with informed patient consent and according to the protocol, and with the approval of the Institutional Review Board #2005-206, Georgetown University, Washington, DC, USA.
Immunohistochemistry
Immunohistochemical labeling of tissues was performed as described earlier (Tang et al., 2003) . Normal human liver and HCC tissues were fixed with 4% paraformaldehyde, dehydrated, embedded in paraffin and sectioned at 6 mm. Sections were immunohistochemically stained using primary antibodies against STAT3 and p Y705 STAT3 (Cell Signaling Technology, Danvers, MA, USA).
The frequency of STAT3-and p Y705 STAT3-positive cells was determined by counting the total number of cells and total positively stained cells in randomly selected 40 Â magnification fields, including at least 1000 cells. Average numbers from the field sets were then determined and reported as the percentage of positively stained cells to the total numbers of cells. Signal transducer and activator of transcription 3 and pSTAT3 labeling was measured in three different grades: þ þ þ , intense labeling (>70%); þ þ , moderate labeling (16-69%); þ , weak labeling (0-15%); and À, no labeling (0%).
Cell cultures
The HCC cell lines HepG2, PLC/PRF/5, Huh-7, SNU-398, SNU-449, SNU-182 and SNU-475 were obtained from American Type Culture Collection, Manassas, VA, USA. HepG2, PLC/PRF/5 and Huh-7 cell lines were maintained in Dulbecco's Modified Eagle's Medium (DMEM). SNU-398, SNU-449, SNU-182 and SNU-475 were maintained in RPMI-1640. Both types of medium were supplemented with 10% fetal bovine serum.
Immunoblot analysis (western blot)
Cell lines were grown in a monolayer up to 70% confluence before harvesting for western blot analysis as described earlier (Tang et al., 2003 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay The MTT assay is based on the conversion of the yellow tetrazolium salt MTT to purple formazan crystals by metabolically active cells (Vistica et al., 1991) . The MTT assay provides a quantitative determination of viable cells. Cells (5 Â 10 3 ) were seeded in 96-well microplates in complete culture medium in the absence or presence of increasing serial dosages of NSC 74859 as indicated. At 72 h after culture, the number of viable cells was measured by adding 100 ml/well of 2 mg/ml MTT solution. After 2 h, the medium was removed, and the formazan crystals were dissolved by adding 100 ml dimethylsulfoxide per well. The absorbance was read at 590 nm with an enzyme-linked immunosorbent assay reader. Each treatment point was performed in 10 wells or sextuplicate (Sigma-Aldrich #M2128).
Magnetic sorting of CD133
þ hepatocellular carcinoma cells Sorting of CD133 þ HCC cells was carried out as described earlier and as per the manufacturer's instructions. Cells were labeled with primary CD133/1 antibody (CD133 mouse IgG1, 10 ml per 10 million cells, conjugated with phycoerythrin, Miltenyi Biotec #130-080-801), and then magnetically labeled with anti-phycoerythrin multisort microbeads (rat anti-mouse, 20 ml per 10 million cells) (Miltenyi Biotec, #130-090-757), followed by separation on the MACS LS column .
Soft-agar colony-formation assay Colony formation assays in soft agar were carried out as described (Turkson et al., 2001) . In brief, a base layer was made by mixing 1% soft agar with an equivalent 2 Â medium and prepared in six-well dishes. CD133-sorted Huh-7 cells were harvested, suspended in medium containing 0.35% soft agar (Invitrogen), and seeded on the base layer at different densities from 5 to 5000 cells per well. All experiments were conducted in triplicate. Plates were maintained at 37 1C in a humidified incubator and were fed every 3 days with 0.1 ml of complete medium. After 2 weeks, the number of colonies formed was counted under the microscope.
Xenograft transplantation and in vivo tumor studies Six-week-old female athymic nude mice were purchased from Harlan (Indianapolis, IN, USA) and maintained in the Five athymic nude mice per group were injected in the left flank area subcutaneously with human HCC Huh-7 cells ranging from 5 Â 10 2 to 5 Â 10 6 in 100 ml of phosphate-buffered saline. After 5-10 days, 10 tumors in the control or treatment group with a diameter of 0.175 mm 3 were established. Animals were given NSC 74859 intraperitoneally at 5 mg/kg every other day for 3 weeks and monitored daily. Animals were stratified so that the mean tumor sizes in all treatment groups were nearly identical. Tumor volume was calculated according to the formula V ¼ 0.5 Â a 2 Â b, where a is the smallest superficial diameter and b is the largest superficial diameter. Student's t-test was used to analyse in vivo growth patterns.
Statistical analysis
Global w 2 test was used to test the hypothesis that the coefficient of each variable was equal to 0. Results from the immunohistochemical labeling of STAT3 and pSTAT3 in HCC samples as compared with normal liver samples were used to assess the statistical significance. Po0.05 was considered statistically significant, and all tests were two-sided. All tests were performed with SPSS 10.1 software (SPSS Inc., Chicago, IL, USA).
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